QNTM Overview

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Wall Street analysts forecast QNTM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNTM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Quantum Biopharma Ltd revenue for the last quarter amounts to -4.68M USD, increased 11.89

Quantum Biopharma Ltd. EPS for the last quarter amounts to -1721476.00 USD, decreased -50.26

Quantum Biopharma Ltd (QNTM) has 0 emplpoyees as of March 11 2026.

Today QNTM has the market capitalization of 10.76M USD.